

DR. AARON FERNANDES

Consultant - Surgical Oncology

Qualification

MBBS | MS (General Surgery) | DrNB (Surgical Oncology)

Overview

Dr. Aaron Marian Fernandes is a highly skilled surgical oncologist in Yelahanka, Bangalore, currently practising as a Consultant – Surgical Oncology at Manipal Hospital Yelahanka. Bringing with him years of focused experience in complex oncological procedures, he is dedicated to delivering precise, compassionate, and evidence-based surgical care to patients across the spectrum of cancer management. His expertise spans breast cancer surgery, thyroid malignancies, and peritoneal surface malignancies, with special proficiency in cytoreductive surgery, HIPEC, and PIPAC procedures. Known for his commitment to improving postoperative outcomes, Dr. Fernandes actively integrates Enhanced Recovery After Surgery (ERAS) protocols into his clinical practice, making him one of the best surgical oncologists in Yelahanka. Dr. Fernandes' academic foundation was led by an MBBS from Father Muller Medical College, Mangalore, an MS in General Surgery and a Doctorate of National Board (DrNB) in Surgical Oncology from Manipal Hospital, Old Airport Road, where he trained under the mentorship of renowned oncologists Dr. Somashekhar S.P. and Dr. Shabber S. Zaveri. His educational and clinical journey reflects an unwavering dedication to mastering both conventional and advanced oncological techniques — including laparoscopic and robotic cancer surgery, which allow for minimally invasive, patient-friendly outcomes. Having also served as Associate Consultant at Aster CMI Hospital, Hebbal, and Senior Resident at St. Martha's Hospital, Bangalore, he has developed a versatile understanding of multidisciplinary cancer care within leading tertiary setups. Dr. Fernandes's core areas of expertise include oncoplastic breast conservation surgery, sentinel lymph node biopsy, thyroid surgeries for malignant and benign conditions, and complex peritoneal cancer resections. His special interest lies in performing cytoreductive surgeries combined with hyperthermic intraperitoneal chemotherapy (HIPEC) and pressurised intraperitoneal aerosol chemotherapy (PIPAC), advanced treatments for peritoneal carcinomatosis. These procedures demand not only surgical precision but also a deep understanding of oncology, patient physiology, and perioperative management, competencies that Dr. Fernandes has honed through years of meticulous practice and international exposure. Beyond surgical excellence, Dr. Fernandes is deeply invested in academic and research endeavours that shape the future of oncological care. His thesis on ERAS protocol implementation in colorectal cancer surgery and his subsequent publications in reputed international journals such as the Journal of Clinical Oncology and Clinical Breast Cancer underscore his commitment to innovation and evidence-based practice. He has contributed to studies addressing psychological outcomes in breast cancer patients, the feasibility of ERAS in CRS-HIPEC, and high-dose chemotherapy regimens in PIPAC, among others. His international certifications and specialised training further complement his professional portfolio — including completion of the ERAS Implementation Program from Lausanne, Switzerland, and PIPAC and HIPEC certification courses from Hannover and international societies such as ISSPP. He is also an Intuitive-certified robotic console surgeon for the Da Vinci X system, demonstrating his commitment to cutting-edge minimally invasive cancer surgery. Dr. Fernandes has been recognised at numerous academic conferences for his research presentations and best paper awards, reflecting both his clinical acumen and scholarly rigour. A life member of multiple national and international associations, including the Indian Association of Surgical Oncology, Association of Breast Surgeons of India, and Society of Surgical Oncology (SSO, USA), Dr. Fernandes actively contributes to collaborative oncological research and academic discussions. His role as a manuscript reviewer for the Indian Journal of Gynecologic Oncology highlights his ongoing contribution to scientific advancement and peer-reviewed excellence in cancer care. With a clinical philosophy grounded in empathy, teamwork, and patient-centred outcomes, Dr. Fernandes continues to uphold the values of precision surgery and holistic cancer management. Patients seeking the best surgical oncologist in Yelahanka trust his expertise not only for his technical mastery but also for his calm, compassionate approach that prioritises safety, recovery, and long-term wellness. At Manipal Hospital Yelahanka, he remains committed to

pushing the frontiers of surgical oncology through research, advanced techniques, and collaborative care models that redefine cancer treatment standards in Bangalore and beyond.

Fellowship & Membership

- Life Member of The Indian Association of Surgical Oncology
- Life Member of the Indian Medical Association and the Association of Surgeons of India
- Life Member of The Bangalore Surgical Society
- Life Member of The Association of Breast Surgeons of India
- Life Member of The Indian Society of Peritoneal Surface Malignancies
- Member of the Society of Surgical Oncology
- Member of the American Society of Clinical Oncology

Field of Expertise

- Breast Oncology
- Thyroid and Endocrine Surgery
- Peritoneal Surface Malignancy
- Minimally Invasive & Robotic Surgery
- Head, Neck & Soft Tissue Oncology
- Gastrointestinal & HPB Oncology
- Intraoperative & Perioperative Management
- Academic & Multidisciplinary Engagement – Active participation in tumour boards, surgical audits, morbidity-mortality meetings, and clinical research initiatives.

Languages Spoken

- English
- Kannada
- Hindi

Awards & Achievements

- “Cytoreductive Surgery with HIPEC as Primary Treatment for Advanced Epithelial Ovarian Carcinoma: Upfront or Interval—ISPSM Collaborative Study”. – Oral Paper Presentation at PSOGI 2023. The 13th PSOGI International Congress on Peritoneal Surface Malignancies.
- “Pressurised Intra-Peritoneal Aerosol Chemotherapy (PIPAC) vs. intravenous chemotherapy for unresectable peritoneal metastases secondary to platinum-resistant ovarian cancer – Interim analysis of an Indian randomised control trial- An ISPSM collaboration study”. – Best Poster At Annual Update In Peritoneal Surface Malignancies Held At Tata Medical Centre, Kolkata, India In April 2023.
- “First Indian study reporting adoption of ERAS in CRS HIPEC: Time to Adopt, Evolve & Improve”. Best Poster At Annual Update In Peritoneal Surface Malignancies Held At Tata Medical Centre, Kolkata, India, In April 2023.
- “A Prospective Comparative Study of Sentinel Lymph Node Biopsy with Indo-Cyanine Green (ICG) Florescence Technique Versus Dual Dye Technique for Early Breast Cancer” – Paper Presentation In Oncostem National Travelling Fellowship In Absicon 2022, Hyderabad, On 12-14 August 2022.
- “A Prospective Observational Study Reporting Early Outcomes of Lymphatic Microsurgical Preventive Healing Approach (Lympha) Procedure After Axillary Lymph Node Dissection” – Best Paper in ABSICON 2022, Hyderabad, on 12-14 August 2022.

- “A Prospective Study of Real-time Identification of Line of Transection in Robotic Colorectal Cancer Surgery by ICG” – Poster presentation at SSO Global Partners Posters Program at the SSO 2022 International Conference on Surgical Cancer Care, in March 2022.
- “A Prospective Study of Real-time Identification of Line of Transection in Robotic Colorectal Cancer Surgery by ICG” –Best Paper Presentation at IASO NATCON 2021, DELHI, IN, December 2021.
- “Prospective Analysis of Robotic-Assisted Rectal Surgery for Carcinoma Rectum: Single Institute Study”- Best Oral Paper IASO 2020 Mid Term Annual Conference of the Indian Association of Surgical Oncology, Organised by Department of Sri Venkateshwara Institute of Medical Sciences, Tirupati in March 2020.
- “Delay in time to adjuvant chemotherapy and its impact on outcome in completely resected advanced ovarian malignancies treated with CRS, CRS+IP and CRS +HIPEC”- Best Oral Poster FOGSI - POGS International Virtual Conference JUST TUMORS - Benign to Malignant Organised by POGS on 11 to 13 December 2020.
- “Impact of Implementation of ERAS program in a Tertiary Care Oncological Centre”- Best Oral Paper presentation during FOGSI - POGS International Virtual Conference JUST TUMORS - Benign to Malignant Organised by POGS on 11 to 13 December 2020.

Talks & Publications

- Prospective Analysis of ERAS protocols (enhanced recovery after surgery) in Colorectal Cancer surgery Thesis: A prospective interventional study on effects of implementation of ERAS protocols in colorectal cancer surgery conducted on 153 consenting patients in Manipal Hospital, HAL Old Airport Rd, Kodihalli, Bengaluru, Karnataka under the guidance of Dr Ashwin K R and Dr Somashekar SP between Nov 2019 – Nov 2021 selected by purposive sampling. Safety and Feasibility of Implementation of ERAS in CRS and HIPEC: Enhancing Recovery or Complications.' Journal of Clinical Oncology, June 2023, vol. 41, no. 16_suppl, pages e18745-e18745. DOI: 10.1200/JCO.2023.41.16_suppl.e18745.
- 'Cyto-reductive Surgery with HIPEC as Primary Treatment for Advanced Epithelial Ovarian Carcinoma: Upfront or Interval—ISPSM Collaborative Study.' Indian Journal of Surgical Oncology, May 2023, vol. 14, Supplement 1, pages 226-232. DOI: 10.1007/s13193-023-01747-3.
- 'An Overview of Psychological Analysis of Breast Cancer Patients Undergoing Modified Radical Mastectomy and Breast Conservation Surgery and Its Impact on Objectified Body Consciousness at a Tertiary Care Cancer Centre in South India.' Clinical Breast Cancer, June 2023, vol. 23, no. 16, DOI: 10.1016/j.clbc.2023.05.017.
- 'Enhanced Recovery After Surgery in Cyto-reductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: National Survey of Peri-operative Practice by Indian Society of Peritoneal Surface Malignancies.' Pleura and Peritoneum, May 2023, vol. 8, no. 2, DOI: 10.1515/pp-2022-0198.
- 'First Clinical Study Reporting Adoption of ERAS in CRS HIPEC as per Published Guidelines: Time to Adopt, Evolve & Improve.' International Journal of Gynaecological Cancer, December 2022, vol. 32, Supplement 3, pages A37.3 A38. DOI: 10.1136/ijgc-2022-igcs.71.
- 'First Report of Clinical Outcomes with Escalated Doses of Cisplatin and Doxorubicin in PIPAC for Peritoneal Carcinomatosis of Epithelial Ovarian Cancer.' International Journal of Gynaecological Cancer, December 2022, vol. 32, Supplement 3, pages A170.1-A170. DOI: 10.1136/ijgc-2022-igcs 381.
- 'First Clinical Study Reporting Safety and Outcomes of High Dose Oxaliplatin Use in PIPAC for Colorectal Peritoneal Carcinomatosis.' Journal of Clinical Oncology, June 2023, vol. 41, no. 16_suppl, pages e15606-e15606. DOI: 10.1200/JCO.2023.41.16_suppl.e15606.